Much Ado About Nothing? Weighing The Impact Of The Institute of Medicine's 510(k) Report
Executive SummaryIndustry and regulators eagerly awaited the Institute of Medicine's 510(k) report, anticipating it could have a major impact on reforming this regulatory path. The result, however, has been one nobody expected: device companies and the FDA united in support of the current program.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.